DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight 2023,” report provides comprehensive insights about 58+ companies and 64+ pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Dry Age-Related Macular Degeneration Emerging drugs, the Dry Age-Related Macular Degeneration pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Dry Age-Related Macular Degeneration pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Dry Age-Related Macular Degeneration Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Dry Age-Related Macular Degeneration clinical trials studies, Dry Age-Related Macular Degeneration NDA approvals (if any), and product development activities comprising the technology, Dry Age-Related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
- DelveInsight’s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 58+ active players working to develop 64+ pipeline therapies.
- The leading Dry Age-related Macular Degeneration Companies include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Promising Dry Age-related Macular Degeneration pipeline therapies include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
- The Dry Age-related Macular Degeneration Companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-Related Macular Degeneration R&D. The Dry Age-related Macular Degeneration pipeline therapies under development are focused on novel approaches to treat/improve Dry Age-Related Macular Degeneration.
Request a sample and discover the recent breakthroughs happening in the Dry Age-Related Macular Degeneration Pipeline landscape @ Dry Age-Related Macular Degeneration Pipeline Outlook Report
Dry Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago.
Recent Developments Activities in the Dry Age- related Macular Degeneration Treatment Landscape
- In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company’s second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
- In June 2021, Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property.
- The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
- In January 2021 Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, had been granted Fast Track designation by the FDA.
- In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
- In December 2020, Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
- On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.
For further information, refer to the detailed Dry Age-Related Macular Degeneration Drugs Launch, Dry Age-Related Macular Degeneration Developmental Activities, and Dry Age-Related Macular Degeneration News, click here for Dry Age-Related Macular Degeneration Ongoing Clinical Trial Analysis
Dry Age-related Macular Degeneration Emerging Drugs Profile
- ALK-001: Alkeus Pharmaceuticals
ALK-001 is once-a-day oral drug candidate currently being tested for the treatment of geographic atrophy (advanced form of dry AMD) and Stargardt disease. Toxic vitamin A aggregates called “dimers” are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers.
- Elamipretide: Stealth BioTherapeutics
Elamipretide (Stealth BioTherapeutics) is a novel tetrapeptide drug currently in development for both common and orphan diseases that involve dysfunction of the mitochondria, the cellular organelles that generates chemical energy in the form of adenosine triphosphate (ATP). At the cellular level, mitochondrial dysfunction causes loss of ATP production, increased levels of reactive oxygen species (eg, superoxide), calcium dysregulation, and, if prolonged, cell death. Elamipretide, given as systemic injection, penetrates tissues and cells and enters the mitochondria, where it reverses mitochondrial dysfunction (improved ATP production, restored mitochondrial membrane potential, normal calcium flux, and reduced superoxide generation).
- CPCB-RPE1: Regenerative Patch Technologies
Regenerative Patch Technologies has developed composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch’s membrane.
- AAV.sFH: Aevitas Therapeutics
AAV.sFH, is an investigational drug being developed by Aevitas Therapeutics. Aevitas advances AAV gene therapies of short-form human factor H (sFH) to restore homeostasis in disorders of complement dysregulation: dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS) and other disorders. sFH restored complement regulation in eyes of FH knockout mice with subretinal administration.
Supraphysiological expression of sFH with subretinal administration was shown in non-human primate eye. Good vector genome transfer to ocular target tissues with intravitreal administration was demonstrated in Yorkshire pigs. Transgene product sFH was present in all eye compartments with potentially clinically relevant FH levels in the porcine eye. Currently, the drug is in Preclinical stage of development for the treatment of Dry AMD.
Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
Find out more about the Dry Age-Related Macular Degeneration Pipeline Segmentation, Therapeutics Assessment, and Dry Age-Related Macular Degeneration Emerging Drugs @ Dry Age-Related Macular Degeneration Treatment Landscape
Scope of the Dry Age-related Macular Degeneration Pipeline Report
- Coverage- Global
- Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Dry Age-Related Macular Degeneration Pipeline Therapies- ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
- Dry Age-related Macular Degeneration Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Dry Age-Related Macular Degeneration Pipeline Companies and Therapies, click here @ Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Dry Age-Related Macular Degeneration: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- ALK-001: Alkeus Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Visomitin: Mitotech
- Drug profiles in the detailed report…..
- Early stage products (Phase I/II)
- RPESC-RPE-4W: Luxa Biotechnology
- Drug profiles in the detailed report…..
- Inactive Products
- Dry Age-Related Macular Degeneration Key Companies
- Dry Age-Related Macular Degeneration Key Products
- Dry Age-Related Macular Degeneration- Unmet Needs
- Dry Age-Related Macular Degeneration- Market Drivers and Barriers
- Dry Age-Related Macular Degeneration- Future Perspectives and Conclusion
- Dry Age-Related Macular Degeneration Analyst Views
- Dry Age-Related Macular Degeneration Key Companies
- Appendix
Got Queries? Find out the related information on Dry Age-Related Macular Degeneration Mergers and acquisitions, Dry Age-Related Macular Degeneration Licensing Activities @ Dry Age-Related Macular Degeneration Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/